Get Unlimited Plan at 75% OFF!
RPG Life Sciences
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
RPG Life Sciences, formerly Searle India Ltd, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The Company is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
The company is having research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. They are having TGA (Aus) and MHRA (UK) approved facilities at Thane in Maharashtra and Ankleshwar in Gujarat.
RPG Life Sciences Ltd was incorporated on March 29, 2007 with the name RPG Pharmaceuticals Ltd. During the year 2007-08, as per the scheme of arrangement, the company acquired the pharmaceuticals business of Brabourne Enterprises Ltd along with all assets and liabilities pertaining to that business with effect from April 2, 2007 (the appointed date). In February 13, 2008, the name of the company was subsequently changed to RPG Life Sciences Ltd.
During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters.
During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments.
The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology.
New products launched were Demator, Sizomax, Mela, Exinia and Mofetyl S during the year 2009-10. The Company strengthened its product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. It launched a new immunosuppressant product, Sirolimus in 2010.
New divisions were launched in highly growing chronic segments namely Cardiology and Diabetic (IMPULSE), NeurologyPsychiatry (EMPATHY) and Oncology (Neo-life). A new division ESSENTIA was also launched to cater to the Hospital sales segment in 2010-11. New products launched were Seretane 2 DT, Rabee 20, Pedimec, Minilactone, Alfalog, Demator, Naprosyn Gel, Lamotrigine dispersible tablets.
The Company sold its Biotech Unit located at Ankleshwar to M/s. Intas Pharmaceuticals Limited as a going concern in 2016-17. It acquired 7 brands from Sun Pharmaceuticals Limited, set up two new divisions viz. Urolife' catering to the urology therapy and Glodiance division catering to the Cosmetic Derma therapy in 2016-17.
In 2017-18, the Company launched brands Darbepoetin (Darba) and Rituximab (XMAB), in the post-transplant care space. Both the brands displayed robust performances in the first year of launch with Darba at third slot among competing Darbepoetin brands. Among the existing products, Immunotac and Arpimune range showed strong growth. In the Africa region, the Company expanded its business with first commercial supply in FY'18. It retained leadership position in Mauritius, through anti-diabetic range while in Egypt, immunosuppressant range remained the best alternative to the innovator brands in the post organ transplant care space.
During 2019, the Company focused on launching new products and driving active promotion in the immunosuppressant range of products and strengthened the oncology portfolio basket by introducing two new monoclonal antibodies. It launched a new product, T-JAKi (JAK Inhibitor) in the immunosuppressant range of products in Rheumatology and Gastroenterology in FY21. As a part of Life Cycle Management strategy of legacy products, Romilast BL and Aldactone T new line extensions were launched. Azoran 75 mg new line extension was launched in 2021. Naprosyn+ and Aldactone-F was launched in FY'22.
RPG Life Sciences share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of RPG Life Sciences indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how RPG Life Sciences is valued compared to its competitors.
RPG Life Sciences PE ratio helps investors understand what is the market value of each stock compared to RPG Life Sciences 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of RPG Life Sciences evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively RPG Life Sciences generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of RPG Life Sciences in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of RPG Life Sciences shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of RPG Life Sciences compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of RPG Life Sciences over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of RPG Life Sciences helps investors get an insight into when they can enter or exit the stock. Key components of RPG Life Sciences Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where RPG Life Sciences shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect RPG Life Sciences ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of RPG Life Sciences provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of RPG Life Sciences highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of RPG Life Sciences .
The balance sheet presents a snapshot of RPG Life Sciences ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App